Bristol-Myers Squibb Foundation awards eight grants totaling nearly $11.5M to make lung and skin cancer screening
- Details
- Category: Bristol-Myers Squibb
To mark National Cancer Prevention Month, the Bristol-Myers Squibb Foundation today announced eight grants totaling nearly $11.5 million that will help make lung and skin cancer screening programs, care and patient support more accessible to underserved populations.
Abbott to Acquire Alere, becoming leader in point of care testing
- Details
- Category: Abbott
Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion.
Merck announces new biopharma heads for North America and China
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced two appointments in two regions important for its biopharma business. Gary Zieziula will lead Merck's biopharma business in North America and Marc Horn will take the helm of the biopharma business in China.
European Commission confirms CMDh recommendation: Benefit/risk profiles of ambroxol and bromhexine products are favorable
- Details
- Category: Boehringer Ingelheim
The European Commission (EC) has taken an EU-wide legally binding decision and confirmed the favorable benefit/risk profile of ambroxol and bromhexine containing medicines. This decision follows the opinion of the Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) as well as the recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) within the European Medicines Agency (EMA).
Merck launches Vivera in Latin America
- Details
- Category: Merck
Merck, a leading science and technology company, today announced the launch of its new consumer brand Vivera® in Latin America. Vivera is being launched first in Chile in January 2016, to be followed by several major Latin American markets later in 2016.
Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in schizophrenia
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS receptors.
Sanofi Pasteur provides key support to the Human Vaccines Project
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of Sanofi, has signed an agreement with the Human Vaccines Project Inc. to partially fund the non-profit, public-private partnership convening leading academic researchers and industrial partners to solve the primary problems impeding vaccine/immunotherapy development by "decoding" the human immune system.
More Pharma News ...
- Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
- Shire to combine with Baxalta, creating the global leader in rare diseases
- Pfizer expands R&D equity investment strategy to access early-stage scientific innovations
- AstraZeneca and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA therapeutics™
- Merck Acquires IOmet Pharma and expands immuno-oncology development program
- Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries
- Sanofi Genzyme announces recipients of Patient Advocacy Leadership (PAL) awards